- Tuesday, 17 February 2015
- AstraZeneca announces Non-Executive Board changes AstraZeneca today announced that Dr Cornelia (Cori) Bargmann will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting (AGM) on 24 April 2015. On election, the Board also proposes appointing Dr Bargmann to AstraZeneca’s Science Committee.
- Friday, 13 February 2015
- US District Court decision in PULMICORT RESPULES® (budesonide inhalation suspension) patent litigation AstraZeneca today announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 (“the ‘834 patent”), protecting PULMICORT RESPULES in the US, is invalid.
- Thursday, 5 February 2015
- AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada AstraZeneca and Actavis Plc today announced that they have entered into a definitive agreement under which AstraZeneca will acquire the rights to Actavis’ branded respiratory business in the US and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold.
- Thursday, 5 February 2015
- AstraZeneca PLC fourth quarter and full year results 2014 Pascal Soriot, Chief Executive Officer, commenting on the results, said: "2014 was a remarkable year for AstraZeneca. We achieved a record six product approvals as we accelerated our pipeline across all main therapy areas. Alongside this, we delivered four quarters of revenue growth, with growth platforms now contributing over half of our revenues. Our strong performance in Emerging Markets is a particular highlight, with China becoming our second largest national market, while the delay in the introduction of Nexium generics in the US helped to direct additional investment towards our launch brands and our rapidly advancing pipeline."
- Wednesday, 4 February 2015
- AstraZeneca receives planning consent for new global R&D centre and corporate headquarters in Cambridge, UK AstraZeneca today announced that Cambridge City Council has granted planning permission for the Company’s new global R&D centre and corporate headquarters in the City. The purpose built facility will be located on the Cambridge Biomedical Campus and will be home to approximately 2,000 employees.
- Thursday, 29 January 2015
- AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform AstraZeneca today announced four research collaborations aimed at harnessing the power of CRISPR, a pioneering genome-editing technique, across its entire discovery platform in the company’s key therapeutic areas. The technology will allow AstraZeneca to identify and validate new drug targets in preclinical models that closely resemble human disease. AstraZeneca will share cell lines and compounds with its partners and work with them to publish findings of its application of CRISPR technology in peer-reviewed journals, contributing to broader scientific progress in the field. The collaborations complement AstraZeneca’s in-house CRISPR programme and will build on the company’s ‘open innovation’ approach to research and development.
- Thursday, 22 January 2015
- Marketing Authorisation Application for gout treatment lesinurad accepted by European Medicines Agency AstraZeneca today announced the European Medicines Agency has accepted the Marketing Authorisation Application (MAA) for lesinurad 200mg tablets. Lesinurad is a selective uric acid reabsorption inhibitor (SURI) developed for the chronic treatment of hyperuricaemia in combination with xanthine oxidase (XO) inhibitors allopurinol or febuxostat in gout patients when additional therapy is warranted.
- Wednesday, 14 January 2015
- PEGASUS-TIMI 54 study of BRILINTA® meets primary endpoint in both 60mg and 90mg doses AstraZeneca today announced that the PEGASUS-TIMI 54 study, a large scale outcomes trial involving over 21,000 patients, successfully met its primary efficacy endpoint. The study assessed BRILINTA® (ticagrelor) tablets at either 60mg twice daily or 90mg twice daily plus low-dose aspirin for the secondary prevention of atherothrombotic events in patients who had experienced a heart attack one to three years prior to study start. The primary efficacy endpoint was a composite of cardiovascular (CV) death, myocardial infarction (MI) or stroke.
- Monday, 12 January 2015
- MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses. This agreement will allow MedImmune to combine key agents from its investigational immunotherapy portfolio with Omnis’ lead investigational oncolytic virus programme, a genetically engineered strain of vesicular stomatitis virus (VSV). The programme is currently being studied in a Phase I clinical trial as a monotherapy for the treatment of hepatocellular carcinoma and other cancers that have metastasised to the liver.
- Friday, 19 December 2014
- LYNPARZA™ approved by the US food and drug administration for the treatment of advanced ovarian cancer in patients with germline BRCA-mutations AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved LYNPARZA™ (olaparib) capsules (400mg twice daily) as the first monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Olaparib has been approved under the FDA’s Accelerated Approval programme, based on existing objective response rate and duration of response data. Continued approval for this indication is contingent upon verification of clinical benefit in ongoing confirmatory Phase III trials.
- 28 Feb
Video: our open collaboration w/ X-Chem has helped us screen compounds to find molecular activity for target proteins http://t.co/yEJondKnwn26 Feb
X-Chem’s DNA-encoded library of billions of compounds has provided leads for us to-date in pain, CV and cancer http://t.co/vDvfltYItd26 Feb